anti-VEGF therapy (Nova Southeastern University/Lombardi Cancer Center of Georgetown University)

N/A

Report date: 2025/06/11 11:22:44
NME

Base Information

Drug Nameanti-VEGF therapy (Nova Southeastern University/Lombardi Cancer Center of Georgetown University)
Drug Alias NameJFDJFD-WSF-16 (Nova Southeastern University)
ClassificationSmall molecules
Mechanisms of ActionAngiogenesis inhibitorsAnticancer protein kinase inhibitorsVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNova Southeastern University
China Registration ClassN/A

Develop Information

Active CompaniesNova Southeastern UniversityLombardi Comprehensive Cancer Center at Georgetown University Hospital
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A